Huiliao Bio was listed on the "Top 100 Chinese Pharmaceutical Innovation Value Discovery" list in 2023.

In November 2023, the "15th China Pharmaceutical Entrepreneurs, Scientists, and Investors Conference" was held in Hangzhou. The event was hosted by the China Pharmaceutical Enterprises Management Association, the China Pharmaceutical Biotechnology Association, the Hangzhou Municipal Bureau of Investment Promotion, and the Linping District Commerce Bureau of Hangzhou, and organized by E-Manager and the China Healthcare Industry Investment 50 Forum. The "2023 China Pharmaceutical Innovation Value Discovery Top 100" list was subsequently released, with Huiliao listed among the honorees.

The China Pharmaceutical Entrepreneurs, Scientists, and Investors Conference has consistently been recognized for its high standards and significant influence within the industry. E-Pharma Manager has established the "LinkValue Value-Leading Innovation Matching Platform" for this event. They invited numerous industry leaders, experts, investors, and Big Pharma BD representatives to comprehensively evaluate 526 projects based on four key dimensions: technological innovation, translational application, market prospects, and the research and development team. From this extensive pool, they selected the "Top 100 Chinese Pharmaceutical Innovation Value Discoveries," with Huiliao successfully chosen after undergoing rigorous professional review.

#About Huiliao Biology#

Huiliao is committed to empowering independent innovation within China's biopharmaceutical industry, building a complete industrialization platform based on its internationally unique mRNA foundational technology. The company is dedicated to developing next-generation vaccines and therapeutic drugs that address critical clinical needs, thereby contributing to the internationalization of Chinese pharmaceuticals.

Huili Bio is a high-tech biotech company specializing in the research and industrialization of nucleic acid drugs. Our business encompasses all aspects of mRNA drug development, including regulatory filings, clinical trial design, data analysis, and industrialization. Centered on our next-generation mRNA delivery system – the cell-like membrane platform – we are developing highly effective vaccines for infectious diseases and cancer, as well as cell therapies and protein replacement therapies, based on our proprietary, original research technologies. We have established a comprehensive "three-in-one" nucleic acid drug R&D and production platform, including the innovative nucleic acid delivery vector CLS (Cell Like System) development platform, the nucleic acid drug Genmax production platform, and a high-throughput, intelligent mRNA design and synthesis platform, all dedicated to the development of next-generation vaccines and therapeutic drugs.